Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine

Journal of Psychiatric Practice

Volumn 15, Issue 6, 2009, Pages 442-448

  Strack, Danielle K ^a   Leckband, Susan G ^b   Meyer, Jonathan M ^b  

^a SHARP HEALTHCARE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reactions; Carbamazepine; Cytochrome P450 induction; P glycoprotein induction; Second generation (atypical) antipsychotic

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CARBAMAZEPINE; CYTOCHROME P450; GLYCERYL TRINITRATE; GLYCOPROTEIN P; HYDROXYZINE; QUETIAPINE; RISPERIDONE;

ADD ON THERAPY; ADULT; ADVERSE DRUG REACTION; ADVERSE OUTCOME; AKATHISIA; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER PROGRAM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; LEUKOCYTE; MALE; MEDICAL DOCUMENTATION; MEDICAL EDUCATION; MEDICAL RECORD REVIEW; MORNING DOSAGE; PRESCRIPTION; PROTEIN INDUCTION; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; VETERAN;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RETROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE;

EID: 75149129651     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000364285.55586.ad     Document Type: Article

References (17)

1. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-1101
2. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drugdisease interactions in the ED: Analysis of a high-risk population. Am J Emerg Med 1996;14:447-450
3. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Car, 2003; 21:153-158
4. Mahmood M, Malone DC, Skrepnek GH, et al. Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm 2007;64:1500-1505
5. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76:391-396
6. Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29:95-118.
7. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005;46:464-494
8. Lacy CF, Armstrong LL, Goldman MP, et al., eds. Drug information handbook: A comprehensive resource for all clinicians and healthcare professionals, 14th edition. Hudson, OH: Lexi-Comp; 2006.
9. Tegretol [package insert]. East Hanover, NJ: Novartis; revised February 2009 (available at www.pharma.us .novartis.com/product/pi/pdf/tegretol.pdf. accessed July 3, 2009).
10. Seroquel [package insert]. Wilmington, DE: AstraZeneca; revised January 2009 (available at www1.astrazenecaus. com/pi/seroquel.pdf, accessed July 3, 2009).
11. Abilify [package insert]. Princeton, NJ: Bristol-Myers Squibb and Otsuka America; revised August 2008 (available at www.abilify.com/pdf/pi.aspx, accessed July 3, 2009).
12. Risperidone [package insert]. Titusville, NJ: Ortho-McNeil Janssen; revised August 2008 (available at www.janssen .com/janssen/shared/pi/risperdal. pdf, accessed July 3, 2009).
13. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69.
14. Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007;27:279-283
15. Preskorn SH. Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!" J Psychiatr Pract 2007;13:328-333
16. Preskorn SH. The difference between the formal and the functional dose: The case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract 2005;11:192-196
17. Takahashi H, Yoshida K, Higuchi H, et al. Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: Two case reports. Clin Neuropharmacol 2001;24: 358-360